Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance PR Newswire SAN DIEGO, Jan. 8, 2025 Reports Preliminary 2024 Unaudited Estimated Ranges Consistent...
Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance PR Newswire SAN DIEGO, Jan. 6, 2025 SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc...
Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia PR...
Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy PR Newswire SAN DIEGO, Dec. 30, 2024 SAN DIEGO...
Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications PR...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | -8.23 | -99.7575757576 | 8.25 | 9.2 | 0.015 | 1259410 | 0.48474389 | CS |
| 260 | -0.405 | -95.2941176471 | 0.425 | 35 | 0.015 | 2666733 | 0.36991871 | CS |
| Symbol | Preis | Vol. |
|---|
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
